Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada

nork Attard, C.L., Maroun, J.A., Alloul, K., Grima, D.T., Bernard, L.M.
Argitaratua 2010

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

nork Grima, D. T., Papaioannou, A., Thompson, M. F., Pasquale, M. K., Adachi, J. D.
Argitaratua izan da Osteoporos Int (2007)